Solution: Reduce volume, not frequency
Semaglutide (or GLP-1 agonists) in real-world settings
have revealed that the activating molecule in beclin1-regulated autophagy (Ambra1) localized to mitochondria may also contribute to autophagosome formation by interacting with Beclin1 [285]
Each episode leaves the central nervous system more damaged, piling on disabilities and eroding the patients quality of life
The takeaway isnt that combination therapy is the answer
Compared with the controls, semaglutide significantly reduced the incidence of atrial fibrillation (AF) (RR 0.73, 95% CI 0.54 to 0.98), complete atrioventricular (AV) block (RR 0.22, 95% CI 0.06 to 0.80), death from CV causes (RR 0.76, 95% CI 0.58 to 0.98), and revascularization (RR 0.68, 95% CI 0.52 to 0.88)